SUBSCRIBE
SUBSCRIBE
News   Drug Development

Viewpoint Molecular Targeting(R) Presents Preclinical Data from VMT-

December 21, 2021 | 
1 min read

Viewpoint Molecular Targeting, Inc. announced the presentation of preclinical data from its theranostic in development, VMT-

  • Optimized 203Pb/212Pb image-guided alpha-particle radionuclide therapy for SST2R expressing tumors
  • Preclinical data of VMT-
Preclinical
ACCESS Newswire
MORE ON THIS TOPIC
Dorval, Quebec, Canada - September 3, 2021: Novartis Pharmaceuticals Canada Inc. head office building in Dorval, Quebec, Canada. Novartis is a global healthcare company based in Switzerland.
Spinal muscular atrophy
Novartis’ Intrathecal Zolgensma Effective in Older Children
March 19, 2025
 · 
6 min read
 · 
Heather McKenzie
Deviation from the plan, path or norms. Choosing an alternative way, changing the plans and flexibility.
Autoimmune disease
Immunovant Will Drop One Myasthenia Gravis Asset, Continuing to Favor Another
March 19, 2025
 · 
1 min read
 · 
Annalee Armstrong
Hand shake icon on wooden cube block which connection with human icon for business deal and agreement concept.
Deals
Servier Nabs Solid Tumor Asset in up to $780M Deal With Black Diamond
March 19, 2025
 · 
2 min read
 · 
Dan Samorodnitsky
Pictured: Sarepta sign on a brick building/courtes
Gene Therapy
Sarepta Shares Crash 22% After Patient on DMD Gene Therapy Elevidys Dies
March 18, 2025
 · 
2 min read
 · 
Tristan Manalac